Study of ChimeriVax™ Dengue Tetravalent Vaccine in Adult Subjects

Inclusion Criteria : * Aged 18 to 40 years on the day of inclusion. * Informed consent form signed. * For a woman, inability to bear a child or negative serum pregnancy test. * Completed the one-year follow-up of Study DIV12. * Able to attend all scheduled visits and to comply with all trial procedures. * For a woman of child-bearing potential: use of an effective method of contraception or abstinence for at least four weeks prior to vaccination and at least four weeks after vaccination. Exclusion Criteria : * History of thymic pathology (thymoma), thymectomy, or myasthenia gravis. * Breast-feeding. * Systemic hypersensitivity to any of the vaccine components or history of a life-threatening reaction to the trial vaccine or a vaccine containing the same substances. * Previous flavivirus vaccination, e.g. Japanese encephalitis or yellow fever. * Current abuse of alcohol or drug addiction that may interfere with the subject's ability to comply with trial procedures. * Planned participation in another clinical trial during the present trial period. * History of flavivirus infection (confirmed either clinically, serologically or microbiologically). * Congenital or acquired immunodeficiency, immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding six months, or long-term systemic corticosteroids therapy. * Chronic illness at a stage that could interfere with trial conduct or completion. * Blood or blood-derived products received in the past three months. * Vaccination planned in the four weeks following the trial vaccination. * Flavivirus vaccination planned during the present trial period. * Planned travel during the present trial period to areas with high dengue endemicity. * Subject deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalised without his/her consent. * Participation in another clinical trial in the four weeks preceding the trial vaccination. * Any vaccination in the four weeks preceding the trial vaccination. * Human Immunodeficiency Virus (HIV), Hepatitis B (Ag HBs) or Hepatitis C (HC) seropositivity in blood sample taken at screening. * Laboratory abnormalities considered clinically significant upon the Investigator's judgement in blood sample taken at screening. * Positive flavivirus serological test in blood sample taken at screening (for Controls only).